비바니 메디컬VANI 주가

[SCHEDULE 13D/A] SCHEDULE 13D/A

[4] 내부자 거래 — PRIMARY DOCUMENT

Here's Why We're Watching Vivani Medical's (NASDAQ:VANI) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update

Initiation of SLIM-1™ clinical trial, a Phase 1 study of NPM-139, a semaglutide implant under development for chronic weight management, on track for mid-year 2026 $28 million in cash, cash equivalents, restricted cash and capital commitments expected to fund current operating plan through the first half of 2027 ALAMEDA, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra

Vivani Medical: Q1 Earnings Snapshot

ALAMEDA, Calif. — ALAMEDA, Calif. — Vivani Medical, Inc. on Wednesday reported a loss of $6.8 million in its first quarter. The Alameda, California-based company said it had a loss of 8 cents...

[10-Q] 분기 실적 — 10-Q

[8-K] 중대 사건 — 8-K

[DEF 14A] 주주총회 위임장 — DEF14A

[ARS] ARS — ARS

[DEFA14A] DEFA14A — DEFA 14A